Lab for Bone Metabolism, Xi'an Key Laboratory of Special Medicine and Health Engineering, Key Lab for Space Biosciences and Biotechnology, Research Center for Special Medicine and Health Systems Engineering, NPU-UAB Joint Laboratory for Bone Metabolism, School of Life Sciences, Northwestern Polytechnical University, Xi'an, Shaanxi, China; Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, China.
Lab for Bone Metabolism, Xi'an Key Laboratory of Special Medicine and Health Engineering, Key Lab for Space Biosciences and Biotechnology, Research Center for Special Medicine and Health Systems Engineering, NPU-UAB Joint Laboratory for Bone Metabolism, School of Life Sciences, Northwestern Polytechnical University, Xi'an, Shaanxi, China.
Bone. 2022 Jan;154:116238. doi: 10.1016/j.bone.2021.116238. Epub 2021 Oct 23.
The migration of osteoblastic cells to bone formation surface is an essential step for bone development and growth. However, whether the migration capacity of osteoblastic cells is compromised during osteoporosis occurrence and how it contributes to bone formation reduction remain unexplored so far. In this work, we found, as a positive regulator of cell migration, microtubule actin crosslinking factor 1 (MACF1) enhanced osteoblastic cells migration. We also examined whether MACF1 could facilitate osteoblastic cells' migration to bone formation surface to promote bone formation through another cytoskeleton protein, microtubule associated protein 1 (MAP1B).
Preosteoblast cell line MC3T3-E1 with different MACF1 level was used for in vitro and in vivo cell migration assay; Primary cortical bone derived mesenchymal stem cells (C-MSCs) from bone tissue of MACF1 conditional knock out (cKO) mice was used for in vitro cell migration assay. Cell migration ability in vitro was evaluated by wound healing assay and transwell assay and in vivo by bone marrow cavity injection. Small interfering RNA (siRNA) was used for knocking down Map1b in MC3T3-E1 cell. Lithium chloride (LiCl) and Wortmannin (Wort) were used for inhibiting/activating GSK3β pathway activity. Luciferase report assay was performed for detection of transcriptional activity of TCF7 for Map1b; Chromatin immunoprecipitation (ChIP) was engaged for the binding of TCF7 to Map1b promoter region.
We found MACF1 enhanced MC3T3-E1 cell and C-MSCs migration in vitro through promoting microtubule (MT) stability and dynamics, and increased the injected MC3T3-E1 cell number on bone formation surface, which indicated a promoted bone formation. We further authenticated that MAP1B had a similar function to MACF1 and was regulated by MACF1 in osteogenic cell, and silencing map1b repressed MC3T3-E1 cell migration in vitro. Mechanistically, by adopting MC3T3-E1 cell with different MACF1 level or treated with LiCl/Wort, we discovered that MACF1 decreased the levels of 1265 threonine phosphorylated MAP1B (p[T1265] MAP1B) through inhibiting GSK3β activity. Additionally, total MAP1B mRNA expression level was upregulated by MACF1 through strengthening the binding of TCF7 to the map1b promoter sequence.
Our study uncovered a novel role of MACF1 in bone formation and MAP1B regulation, which suggested that MACF1 could be a potential therapeutic target for osteoporosis.
成骨细胞向骨形成表面的迁移是骨发育和生长的关键步骤。然而,成骨细胞的迁移能力在骨质疏松症发生时是否受到损害,以及它如何导致骨形成减少,目前仍不清楚。在这项工作中,我们发现微管肌动蛋白交联因子 1(MACF1)作为细胞迁移的正调节剂,增强了成骨细胞的迁移。我们还研究了 MACF1 是否可以通过另一种细胞骨架蛋白微管相关蛋白 1(MAP1B)促进成骨细胞向骨形成表面的迁移,从而促进骨形成。
使用不同 MACF1 水平的前成骨细胞系 MC3T3-E1 进行体外和体内细胞迁移实验;使用来自 MACF1 条件性敲除(cKO)小鼠骨组织的原代皮质骨来源间充质干细胞(C-MSCs)进行体外细胞迁移实验。通过划痕愈合实验和 Transwell 实验评估体外细胞迁移能力,通过骨髓腔注射评估体内细胞迁移能力。使用小干扰 RNA(siRNA)敲低 MC3T3-E1 细胞中的 Map1b。使用氯化锂(LiCl)和渥曼青霉素(Wort)抑制/激活 GSK3β 通路活性。进行荧光素酶报告实验检测 TCF7 对 Map1b 的转录活性;采用染色质免疫沉淀(ChIP)实验检测 TCF7 与 Map1b 启动子区域的结合。
我们发现 MACF1 通过促进微管(MT)稳定性和动态性来增强 MC3T3-E1 细胞和 C-MSCs 的迁移,并增加注射到骨形成表面的 MC3T3-E1 细胞数量,这表明促进了骨形成。我们进一步证实 MAP1B 具有类似于 MACF1 的功能,并在成骨细胞中受到 MACF1 的调节,沉默 map1b 可抑制 MC3T3-E1 细胞的体外迁移。在机制上,通过采用不同 MACF1 水平的 MC3T3-E1 细胞或用 LiCl/Wort 处理,我们发现 MACF1 通过抑制 GSK3β 活性降低了 1265 丝氨酸磷酸化 MAP1B(p[T1265]MAP1B)的水平。此外,MACF1 通过增强 TCF7 与 map1b 启动子序列的结合,上调了总 MAP1B mRNA 表达水平。
我们的研究揭示了 MACF1 在骨形成和 MAP1B 调节中的新作用,这表明 MACF1 可能是骨质疏松症的潜在治疗靶点。